samedan logo
 
 
 
spacer
home > pmps > summer 2018 > smarter technology
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Smarter Technology

Currently, patients with asthma and chronic obstructive pulmonary disease (COPD) rely on metered-dose inhalers (MDIs) and dry powder inhalers (DPIs) to deliver critical medication to their lungs. However, there is room for human error with each and every dose. In fact, an alarming number of patients make mistakes when using their inhalers. Research shows 94% of DPI users and 76% of MDI users do not use their devices properly (1). Furthermore, findings indicate low device competence only continues to rise (2).

The mistakes and misuse can be attributed to a number of factors. In the first place, inhalers – which seem simple on the surface – can be complicated to use. Patients must often rely on their healthcare providers to teach them how to use the devices properly. However, those providers often do not receive proper training themselves on the device’s correct use.

To further complicate matters, research shows a low adherence rate among asthma and COPD patients. One study found only 25% of COPD patients use inhaled medications every day (3). Among asthma patients, up to 70% do not adhere to prescribed medication (4). It goes without saying that, if medication is not delivered correctly, it will be ineffective. When patients are not properly using their inhalers or simply not using them at all, they are not getting the important medication necessary to maintain their health and well-being. Put simply, their health is at risk. MDIs have not changed much in the decades since they were first invented, which is a huge point of frustration for healthcare providers who have long been aware of these problems. Even if they could convince their patients to use their inhalers consistently, the other half of the battle remains. Maureen George, PhD, RN, from the Columbia University Medical Center says, “Adherence alone with bad technique is not going to improve conditions or quality of life for asthma or COPD patients.”

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Excited by the ways technology can improve healthcare outcomes, Sam Van Alstyne is a software engineer who ventured into marketing and has since become passionate about digital health. As the new Products Marketing Leader in 3M’s Drug Delivery Systems Division, he is responsible for connected respiratory programmes.
spacer
Sam Van Alstyne
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Bormioli Pharma runs Envision 2020: A Digital Event to Showcase The New Strategic Directions, Brand-New Product Portfolios and Prototypes

Parma, 24 November 2020 – Bormioli Pharma will showcase its brand-new product portfolios, products and prototypes during “Bormioli Pharma Envision 2020”, a digital event that will take place in the first half of December open to all the stakeholders. The event will be the occasion to get in touch with the leading European pharma packaging manufacturer in glass and plastic in such hectic times for the industry. Even during the Covid-19 pandemic, the company has kept the momentum for its expansion and growth process, finalizing new investments and M&As to enlarge its industrial platform and the products range.
More info >>

White Papers

The Power of Execution in Clinical Research

Medpace

Medpace, long known for its excellence in conducting Phase I-IV studies on a global platform, is particularly noted for its therapeutic excellence. When that expertise is combined with operational precision, the results are nothing short of stellar. The Medpace full-service outsourcing approach – combined with therapeutic expertise, regulatory know how, and global presence – delivers clinical studies with an industry recognized track record.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement